OncoCyte (OCX) Analyst Estimates Annual - Discounting Cash Flows
OncoCyte Corporation
OCX (AMEX)

* (except for per share items) of USD
Period Ending: 2026
12-31
2025
12-31
2024
12-31
2023
12-31
2022
12-31
2021
12-31
2020
12-31
2016
12-31
Number of Analysts 1 2 1 2 0 1 1 19
Estimated Revenue
Low
Average
High
Estimated EBITDA
Low
Average
High
Estimated EBIT
Low
Average
High
Estimated Net Income
Low
Average
High
Estimated SGA Expenses
Low
Average
High
Estimated EPS
Low -1.76 -1.83 -2.62 -4.47 -8.21 -8.90 -10.48 -9.07
Average -1.54 -1.52 -2.29 -3.91 -7.17 -8.20 -9.65 -8.35
High -1.33 -0.89 -1.97 -3.36 -6.17 -7.52 -8.85 -7.66
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us